INS and type 2 diabetes mellitus: Patients over 18 years old with T2DM, HbA1c between ≥7.5% and ≤11%, treated for at least 90 days prior to the day of screening with once or twice daily basal insulin with or without a stable dose of metformin ≥1500 mg/day and up to maximum approved dose per country-specific approved label, sulfonylureas or dipeptidyl peptidase 4 inhibitors, andBMI ≥23kg/m2 ≤45 kg/m2 and stable weight (± 5%) for at least 90 days